This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Dominance abuse probe of Nantong Jinghua suspended after corrective actions

( March 8, 2019, 09:58 GMT | Official Statement) -- MLex Summary: The Jiangsu provincial Administration for Market Regulation on Feb. 20 decided to suspend its antitrust investigation of Nantong Jinghua Pharmaceutical over abuses of dominance, after the company proposed and implemented a series of corrective measures to eliminate the anticompetitive impact of its conduct. From July 2013 to December 2015, Nantong Jinghua refused to supply phenobarbital, a sedative hypnotic drug, to several downstream drug manufacturers, which reduced competition and led to increases in its price. The regulator opened its probe of the case in July 2016.The statement follows and the text of the decision is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections